Yazar "Carlioglu, Ayse" seçeneğine göre listele
Listeleniyor 1 - 7 / 7
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome(Springer Heidelberg, 2014) Karakurt, Feridun; Carlioglu, Ayse; Kaygusuz, Ikbal; Gumus, Ilknur Inegol; Uz, Burak; Akdeniz, DeryaOur study was undertaken to evaluate the levels of asymmetric dimethyl-arginine (ADMA) in a group of patients affected with polycystic ovary syndrome (PCOS)-under ethinyl estradiol-cyproterone acetate treatment or not-as compared with a group of healthy controls. Fifty-eight women with PCOS and 45 patients as control group were included in the study. The 58 women with PCOS were separated into two groups: Group A (n = 29) were treated with an oral contraceptive pill containing 0.035 mg of ethinyl estradiol (EE) and 2 mg of cyproterone acetate (CA) (Diane-35) for 6 months. Group B (n = 29) did not take any drug. Group C (n = 45) was healthy women as control group. Serum levels of ADMA, lipid and glucose metabolism parameters, hormone profile were measured on the sixth month of treatment. ADMA levels were similar in women with PCOS and controls, whereas ADMA levels significantly decreased after a period of 6 months treatment with EE + CA in women with PCOS. ADMA levels and insulin resistance were decreased with treatment. However, patients with PCOS had significantly higher total cholesterol and Low-density lipoprotein cholesterol (LDL-C) compared to controls, treatment with EE + CA did not provide any improvement on lipid parameters. Serum ADMA levels and insulin resistance were lower in PCOS group treated with EE + CA than control group.Öğe Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome(Springer, 2014) Ademoglu, Esra Nur; Gorar, Suheyla; Carlioglu, Ayse; Yazici, Havva; Dellal, Fatma Dilek; Berberoglu, Zehra; Akdeniz, DeryaBackground Nesfatin-1 is a recently discovered neuropeptide derived from its precursor nucleobindin-2 (NUCB2) and has been implicated in the regulation of feeding and energy metabolism. It is located in the brain and also produced at the periphery and present in the plasma. However, its pathophysiological role in humans remains unknown. Polycystic ovary syndrome (PCOS) is commonly presented with obesity, insulin resistance, hyperandrogenemia and hirsutism. Aim To characterize serum nesfatin-1 levels in PCOS women and determine association of nesfatin-1 with metabolic parameters. Materials and methods It is a cross-sectional study of 55 PCOS and 28 healthy women matched in age, in a university hospital setting. Anthropometric, hormonal, metabolic parameters and nesfatin-1 blood levels were determined. Results Nesfatin-1 levels were significantly higher in PCOS group compared with the controls 371.43 +/- 2.50 versus 275.55 +/- 1.74 pg/mL. Multivariate logistic regression analysis that contains: nesfatin-1, body mass index and homeostasis model assessment index revealed significant correlation of nesfatin-1 with the existence of PCOS (p < 0.05). Conclusions Higher nesfatin-1 levels in PCOS women compared to control group may suggest a possibility that nesfatin-1 may play some role in the PCOS.Öğe Role of ?-glutamyl transferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease(Wolters Kluwer Medknow Publications, 2016) Kasapoglu, Benan; Turkay, Cansel; Yalcin, Kadir Serkan; Carlioglu, Ayse; Koktener, AsliBackground & objectives: Non-alcoholic fatty liver disease (NAFLD) is an important cause of elevated liver functions. There is evidence showing an association between NAFLD and subclinical atherosclerosis independent of traditional risk factors. We undertook this retrospective study to determine the association of Framingham cardiovascular risk scoring system with liver function tests and inflammatory markers and to find the role of liver function tests in determination of CVD risk among non-obese and nondiabetic subjects with non-alcoholic fatty liver disease. Methods: A total of 2058 patients were included in the study. Framingham cardiovascular risk scoring was done of all patients according to the age, gender, systolic blood pressure, serum total cholesterol and HDL cholesterol levels, smoking and antihypertensive medication history. Liver function test, lipid profile, insulin, uric acid, ferritin levels, etc. were determined. Results: According to the ultrasonography findings, patients were grouped as without any fatty infiltration of the liver (control group) (n= 982), mild (n= 473), moderate (n= 363) and severe fatty liver disease (n= 240) groups. In severe fatty liver disease group, the mean Framingham cardiovascular risk score was significantly higher than that of other groups. There was a positive correlation between GGT, uric acid and ferritin levels with Framingham cardiovascular score. In multivariate analysis, high GGT levels were positively associated with high-risk disease presence (OR: 3.02, 95% CI: 2.62-3.42) compared to low GGT levels independent of the age and sex. Interpretation & conclusions: Cardiovascular disease risk increases with the presence and stage of fatty liver disease. Our findings showed a positive correlation between elevated GGT levels and Framingham cardiovascular risk scoring system among non-diabetic, non-obese adults which could be important in clinical practice. Though in normal limits, elevated GGT levels among patients with fatty liver disease should be regarded as a sign of increased cardiovascular disease risk. Larger studies are warranted to elucidate the role of GGT in prediction of cardiovascular risk.Öğe Serum nesfatin-1 levels are decreased in pregnant women newly diagnosed with gestational diabetes(Sbem-Soc Brasil Endocrinologia & Metabologia, 2017) Ademoglu, Esra Nur; Gorar, Suheyla; Keskin, Muge; Carlioglu, Ayse; Ucler, Rifki; Erdamar, Husamettin; Culha, CavitObjective: To investigate serum nesfatin-1 levels at 24-28 weeks of pregnancy in women newly diagnosed with gestational diabetes and determine the association of nesfatin-1 with several metabolic parameters. Subjects and methods: Forty women newly diagnosed with gestational diabetes at 24-28 weeks of pregnancy and 30 healthy pregnant women matched in age and gestational week were included in this cross-sectional study. Serum nesfatin-1 levels were analyzed using ELISA, and the relationship between nesfatin-1 and several metabolic parameters were assessed. Results: Serum nesfatin-1 levels were found to be lower in women with gestational diabetes compared to the pregnant women in the control sample (p = 0.020). Multiple linear regression analysis revealed that nesfatin-1 was lower in participants with gestational diabetes independently from gestational age, BMI, HOMA-IR, fasting plasma glucose, and age. In correlation analysis, the only variable that was found to have a statistically significant correlation with nesfatin-1 was gestational age (p = 0.015, r = 0.30). Conclusion: Lower nesfatin-1 levels in women with gestational diabetes compared to the control group at 24-28 weeks of gestation draws attention to nesfatin-1 levels in gestational diabetes and motivates further research in this area.Öğe The Effect of Zofenopril on Pancreas, Kidney and Liver of Diabetic Rats(Turk Nefroloji Diyaliz Transplantasyon Dergisi, 2014) Carlioglu, Ayse; Akdeniz, Derya; Alkan, Rabia; Uz, Ebru; Haltas, Hacer; Turgut, Faruk; Uysal, SemaOBJECTIVE: Oxidative stress is responsible for some important complications of diabetes mellitus. Zofenopril, which has an antioxidant effect, may decrease the oxidative stress of the diabetic microenvironment. The aim of our study was to evaluate the effect of zofenopril in the liver, pancreas and kidney of alloxan- induced diabetic rats. MATERIAL and METHODS: Rats were divided into five groups: control group (n=6), rats treated with zonenopril (50 mg/kg/day, orally four weeks; n=6), rats exposed to alloxane (120 mg/kg single dose intraperitoneal injection, n=6), rats administered alloxan+ zofenopril (n=6) and rats administered insulin plus alloxan. RESULTS: After one month, we observed histological improvement in the kidneys but not in the pancreas and liver. CONCLUSION: In conclusion, zofenopril may be effective on the renal complications of diabetes mellitus.Öğe The effects of thyroid hormones on uroflowmetry parameters in asymptomatic women(Tubitak Scientific & Technological Research Council Turkey, 2013) Cimentepe, Ersin; Yildirim, Mehmet Erol; Incebay, Ilkay Bekir; Carlioglu, Ayse; Karatas, Omer Faruk; Unal, DoganAim: To investigate whether there is any association between uroflowmetry parameters and blood levels of thyroid hormones in asymptomatic women. Materials and methods: Included in the study were 110 consecutive female patients with no urinary complaints who had thyroid function tests performed in an endocrinology clinic. Uroflowmetric measurements were performed for each patient in a sitting position. The patients were divided into 3 groups, hypo-, hyper-, and euthyroidism, and were investigated for statistical difference among them regarding maximum flow rate (Qmax), average flow rate (Qave), voided volume (VV), and voiding time (VT). Results: The mean Qmax and Qave values of hypo-, eu-, and hyperthyroid groups were 25.3 +/- 9.1 and 14.9 +/- 5.8, 28.6 +/- 9.6 and 16.2 +/- 6.4, and 21.5 +/- 8.7, and 13.2 +/- 5.6, respectively. In the evaluation of all groups, a statistically significant difference was found regarding Qmax (P = 0.004) and Qave (P = 0.024). When the groups were evaluated between each other, Qmax (p = 0.003) and Qave (P = 0.027) were significantly different between hyper- and euthyroid groups, with no statistically significant differences in other groups regarding the uroflowmetry parameters (P > 0.05). Conclusion: It has been found that Qmax and Qave were significantly lower in the hyperthyroid group as compared with the euthyroid group. According to these findings, it may be thought that hyperthyroidism negatively affects uroflowmetry parameters. To reach a definitive judgment, more investigations supported by urodynamic studies are necessary.Öğe The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome(Springer Heidelberg, 2014) Carlioglu, Ayse; Kaygusuz, Ikbal; Karakurt, Feridun; Gumus, Ilknur Inegol; Uysal, Aysel; Kasapoglu, Benan; Armutcu, FerahPurpose To evaluate the platelet activating factor acetyl hydrolyze (PAF-AH), oxidized low-density lipoprotein (ox-LDL), paraoxonase 1 (PON1), arylesterase (ARE) levels and the effects of metformin and Diane-35 (ethinyl oestradiol + cyproterone acetate) therapies on these parameters and to determine the PON1 polymorphisms among PCOS patients. Methods Ninety patients with PCOS, age 30, and body mass index-matched healthy controls were included in the study. Patients were divided into three groups: metformin treatment, Diane-35 treatment and no medication groups. The treatment with metformin or Diane-35 was continued for 6 months and all subjects were evaluated with clinical and biochemical parameters 6 months later. One-way Anova test, t test and non-parametric Mann-Whitney U tests were used for statistical analysis. Results PAF-AH and ox-LDL levels were statistically significantly higher in untreated PCOS patients than controls, and they were statistically significantly lower in patients treated with metformin or Diane-35 than untreated PCOS patients. In contrast, there were lower PON1 (not statistically significant) and ARE (statistically significant) levels in untreated PCOS patients than the control group and they significantly increased after metformin and Diane-35 treatments. In PCOS patients serum PON1 levels for QQ, QR and RR phenotypes were statistically significantly lower than the control group. Conclusion In patients with PCOS, proatherogenic markers increase. The treatment of PCOS with metformin or Diane-35 had positive effects on lipid profile, increased PON1 level, which is a protector from atherosclerosis and decreased the proatherogenic PAF-AH and ox-LDL levels.
